The present status of tumor immunology.
D000818:Animals; D000917:Antibody Formation; D000937:Antigen-Antibody Reactions; D000941:Antigens; D000951:Antigens, Neoplasm; D000956:Antigens, Viral; D001323:Autoantibodies; D006084:Graft Rejection; D006168:Guinea Pigs; D006650:Histocompatibility Testing; D006801:Humans; D006968:Hypersensitivity, Delayed; D007108:Immune Tolerance; D007110:Immunity, Active; D007111:Immunity, Cellular; D007112:Immunity, Maternally-Acquired; D007116:Immunization, Passive; D007153:Immunologic Deficiency Syndromes; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007519:Isoantigens; D008198:Lymph Nodes / Q000276:immunology; D008214:Lymphocytes; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000276:immunology; D008545:Melanoma / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D009362:Neoplasm Metastasis / Q000517:prevention & control; D009365:Neoplasm Regression, Spontaneous; D009369:Neoplasms / Q000276:immunology*; D009374:Neoplasms, Experimental / Q000139:chemically induced; D012516:Osteosarcoma / Q000276:immunology; D011817:Rabbits; D051381:Rats; D012641:Selection, Genetic; D014780:Viruses / Q000276:immunology
D000941:Antigens; D000951:Antigens, Neoplasm; D000956:Antigens, Viral; D001323:Autoantibodies; D007519:Isoantigens